Bio News
Altimmune’s GLP-1/glucagon dual agonist pemvidutide reduced heavy-drinking days by 4.2 days and lowered an alcohol consumption biomarker by 38% in a phase 2 clinical trial for alcohol use disorder (AUD). In the 24-week trial, the biomarker increased by 5.9% in the placebo group, achieving statistical significance. Based on these results, Altimmune plans to consult with the US Food and Drug Administration (FDA) and begin a phase 3 trial for metabolic dysfunction-associated steatohepatitis (MASH) later this year.
BIOBOOK TEAM
biobookmedia@biobook.co.krRural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
HLB Submits FDA Resubmission for First-Line Liver Cancer Treatment
Celltrion Reports Third-Quarter Revenue of 1.5 Trillion Won and Operating Profit of 510 Billion Won, Up 69% Year Over Year
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
